http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#Head http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#assertion http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#provenance http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#pubinfo http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#assertion http://purl.obolibrary.org/obo/DOID_10763 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_10763 http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00381 http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association http://www.w3.org/2000/01/rdf-schema#label amlodipine besylate tablet usp is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension 1 1 o amlodipine besylate tablet usp is indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions coronary artery disease 1 2 o chronic stable angina o vasospastic angina prinzmetal s or variant angina o angiographically documented coronary artery disease in patients without heart failure or an ejection fraction 4 amlodipine besylate tablet usp is indicated for the treatment of hypertension to lower blood pressure lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events primarily strokes and myocardial infarctions these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablet usp control of high blood pressure should be part of comprehensive cardiovascular risk management including as appropriate lipid control diabetes management antithrombotic therapy smoking cessation exercise and limited sodium intake many patients will require more than one drug to achieve blood pressure goals for specific advice on goals and management see published guidelines such as those of the national high blood pressure education program s joint national committee on prevention detection evaluation and treatment of high blood pressure jnc numerous antihypertensive drugs from a variety of pharmacologic classes and with different mechanisms of action have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality and it can be concluded that it is blood pressure reduction and not some other pharmacologic property of the drugs that is largely responsible for those benefits the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly elevated systolic or diastolic pressure causes increased cardiovascular risk and the absolute risk increase per mmhg is greater at higher blood pressures so that even modest reductions of severe hypertension can provide substantial benefit relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk so the absolute benefit is greater in patients who are at higher risk independent of their hypertension for example patients with diabetes or hyperlipidemia and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal some antihypertensive drugs have smaller blood pressure effects as monotherapy in black patients and many antihypertensive drugs have additional approved indications and effects e g on angina heart failure or diabetic kidney disease these considerations may guide selection of therapy amlodipine besylate tablet usp may be used alone or in combination with other antihypertensive agents chronic stable angina amlodipine besylate tablet usp is indicated for the symptomatic treatment of chronic stable angina amlodipine besylate tablet usp may be used alone or in combination with other antianginal agents vasospastic angina prinzmetal s or variant angina amlodipine besylate tablet usp is indicated for the treatment of confirmed or suspected vasospastic angina amlodipine besylate tablet usp may be used as monotherapy or in combination with other antianginal agents angiographically documented cad in patients with recently documented cad by angiography and without heart failure or an ejection fraction 4 amlodipine besylate tablet usp is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00381 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#provenance http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#pubinfo http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#sig http://purl.org/nanopub/x/hasSignature Ysn7Zw9cQ7a45V+SOyV/nYTKCqNZYBUK8OmFuinICfj/NcRrH+Y+SXgEBZc/p2+QZ8UlB9XT/pI1T8/G6wMr2JkS4pgcIYtMc68qELq2N6AdC8LvjHe+9JMMZxUv4PmY63lJYa75fqCw3AHsjTRSGNPEGrySeBcssZ3OtAoTdM8= http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 http://purl.org/dc/terms/created 2021-06-13T15:20:02.493+02:00 http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA6l3K41bf-d39gx4Rr92wfqu061Al3Ys9Elp6mwNw_r0 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs